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AbstrACt 
background Diarrhoea-associated mortality and 
morbidity are highest in infants and young children 
in low-income and middle-income countries (LMICs). 
Zinc supplementation during acute diarrhoea has been 
shown to reduce the duration of illness and the risk 
of persistent diarrhoea. However, vomiting with zinc 
supplementation is a common side effect that may 
interfere with compliance and programmatic scale-up, 
and may be related to the dose prescribed.
Methods/design The Zinc Therapeutic Dose Trial 
(ZTDT) is a two-centre (Tanzania and India), three-arm 
randomised, double-blind controlled non-inferiority trial. 
Children 6–59 months of age with acute diarrhoea are 
eligible to participate. Enrolled children (1500 per arm; 
4500 total) will be randomly allocated to receive 5, 10 
or 20 mg of zinc sulfate daily for 14 days and will be 
followed up for 60 days after enrolment. All children 
will receive WHO/Unicef Integrated Management of 
Childhood Illness standard of care (oral or intravenous 
rehydration and zinc as indicated and feeding advice). 
The primary efficacy outcomes of the trial are the 
percentage of subjects with diarrhoea duration >5 
days, the mean total number of loose or watery stools 
after enrolment and the proportion of children vomiting 
within 30 min of zinc administration.
Discussion The ZTDT trial will determine the optimal 
dose of therapeutic zinc supplements for treatment 
of acute diarrhoea in children aged 6–59 months in 
two LMICs. The results of the trial are likely to be 
generalisable to childhood acute diarrhoea in similar 
resource-limited settings and may influence global 
policy about zinc supplementation dosage during acute 
diarrhoea.
trial registration number NCT03078842.
trial status Enrolment began in January 2017 and 
follow-up is estimated to be completed by April 2019. As of 
1 February 2019, 742 children are still contributing data to 
the ZTDT study.
bACkgrounD
Zinc is a vital micronutrient essential for 
protein synthesis, cell growth and differenti-
ation, immune function, and intestinal trans-
port of water and electrolytes.1 Zinc is also 
important for normal growth and develop-
ment of children both with and without diar-
rhoea.2 Zinc deficiency is associated with an 
increased risk of gastrointestinal infections, 
altered structure and function of the gastro-
intestinal tract and impaired immune func-
tion.3–5 Dietary deficiency of zinc is especially 
common in low-income countries because 
of a low dietary intake of zinc-rich foods 
What is already known on this topic?
 ► Therapeutic zinc supplementation has been recom-
mended by WHO/Unicef for standard diarrhoea case 
management since 2004.
 ► Research evidence had shown zinc reduced the du-
ration and severity of the acute diarrhoea, and low-
ered the risk of persistent diarrhoea.
 ► However, many trials noted that current dosage 
(20 mg/day for children aged  >6 months) is asso-
ciated with vomiting and possibly poor compliance.
What this study hopes to add?
 ► This study evaluates whether lower doses of zinc 
(10 mg/5 mg) are non-inferior to the standard dose 
in efficacy but superior for vomiting.
 ► If vomiting is less frequent and efficacy is main-
tained with low-dose zinc, caregiver acceptability 
may improve, leading to greater utilisation and bet-
ter health outcomes.
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(including foods of animal origin) or low bioavailability 
due to the presence of phytates often found in cere-
al-based diets.1 
The benefits of zinc supplementation in the manage-
ment of diarrhoea have been observed in several studies. 
Patel et al6 noted in a systematic review and meta-analysis 
an approximate 20% reduction in the mean duration of 
acute diarrhoea with zinc supplementation. Lazzerini and 
Wanzira,7 summarising data from 2581 children from 9 
trials, noted that children older than 6 months receiving 
zinc supplements had a shorter diarrhoea duration by 
about half a day (mean difference −11.46 hours, 95% CI 
−19.72 to −3.19). A reduction in diarrhoea that continues 
up to day 7 (risk ratio 0.73, 95% CI 0.61 and 0.88) was also 
noted in this study. Moreover, the study indicated that 
zinc supplements in children with persistent diarrhoea 
(defined as diarrhoea for >14 days) also may shorten 
average diarrhoea duration by 16 hours (mean difference 
−15.84 hours, 95% CI −25.43 to −6.24). As a result of these 
and other trials, since 2005 WHO/Unicef have recom-
mended routine zinc supplementation (10 mg daily for 
infants below 6 months of age; 20 mg daily for children 
older than 6 months) for 10–14 days.8
These doses, however, were not chosen after dose-
ranging studies, and substantially exceed the recom-
mended dietary allowances (RDA) for zinc in infancy and 
early childhood (2–5 mg/day).9 High doses of zinc can 
cause epigastric pain and lethargy, and its metallic taste 
can also induce vomiting. Vomiting with zinc supple-
ments is a common side effect noted in many published 
trials. A meta-analysis by Lukacik et al 3summarised the 
findings for acute and persistent diarrhoea from a total 
of 22 zinc intervention trials, using a range of zinc dosing 
(5–45 mg/day). In 11 acute diarrhoea trials (n=4438), 
the proportion of participants who vomited after the 
initial dose was significantly higher with zinc use than 
with placebo (12.7% vs 7.6%; relative risk [RR]: 1.55; 
95% CI: 1.30 to 1.84; p≤0.001). According to the review 
by Lazzerini and Wanzira,7 the risk of vomiting increased 
with zinc supplementation in both children older than 
age 6 months (risk ratio 1.57, 95% CI 1.32 to 1.86; 2605 
children, 6 trials) as well as children younger than 6 
months of age (risk ratio 1.54, 95% CI 1.05 to 2.24; 1334 
children, 2 trials). Other studies have also reported that 
therapeutic zinc supplementation during diarrhoea 
causes higher rates of vomiting.10–12
Thus, although substantial evidence supports the effi-
cacy of zinc supplementation during episodes of diar-
rhoea, vomiting is significantly more common among 
supplemented children. Lower doses of zinc, provided 
they are equally effective, might have the advantage 
of reducing side effects, increasing compliance and 
programmatic roll-out. If the zinc dose for diarrhoea 
treatment and zinc deficiency can be uniform, then the 
national essential drug lists can be simplified. Therefore, 
there exists an important rationale to identify the dose of 
zinc supplementation associated with both efficacy and 
an improved safety profile. We present the protocol for a 
two-centre, randomised, double-blind controlled trial of 
three doses of zinc conducted in Tanzania and India. The 
overall goals of the study are to evaluate the non-inferi-
ority, safety and acceptability of the two lower zinc doses 
(5 and 10 mg/day) versus standard zinc dose (20 mg/
day).
MethoDs
study design
The Zinc Therapeutic Dose Trial (ZTDT) is an individu-
ally randomised, parallel-group, double-blind, controlled 
trial of three doses of supplemental zinc conducted 
among 4500 children aged 6–59 months in India and 
Tanzania ( ClinicalTrials. gov identifier NCT03078842).
The trial protocol was developed by collaborators at 
WHO, Department of Maternal Newborn, Child and 
Adolescent Health (Geneva, Switzerland) together with 
teams in New Delhi, India (Centre for Public Health 
Kinetics), Dar es Salaam, Tanzania (Muhimbili University 
of Health and Allied Sciences) and Boston, USA (Boston 
Children’s Hospital and Harvard TH Chan School of 
Public Health). The ZTDT protocol diagram is presented 
in online supplementary additional file 1. The schedule 
of trial enrolment, interventions and assessments is 
presented in online supplementary additional file 2. The 
first participant was enrolled in the trial in January 2017 
in India and March 2017 in Tanzania and follow-up data 
collection will continue through approximately April 
2019. This paper follows the Standard Protocol Items: 
Recommendations for Interventional trials (SPIRIT) 
checklist (see online supplementary additonal file 3).
The study population will include 4500 children 
aged 6–59 months with diarrhoea of <72 hours dura-
tion. Enrolled children will be followed up for 60 days 
after randomisation. The participant will be followed 
up closely for the first 15 days to record postinterven-
tion morbidity outcomes and to ensure compliance with 
study regimen. Study participants will be assessed again at 
30, 45 and 60 days postenrolment to estimate impact on 
long-term morbidity outcomes.
Patient and public involvement
This research was done without patient involvement. 
Patients were not invited to comment on the study 
design and were not consulted to develop patient rele-
vant outcomes or interpret the results. Patients were 
not invited to contribute to the writing or editing of this 
document for readability or accuracy.
Primary and secondary objectives
The overall aim of ZTDT is to identify the optimal dose 
of zinc in children under 5 years with acute diarrhoea.
The primary aims of the study are: (1) to assess whether 
lower doses of zinc (5 or 10 mg/day) are at least as effec-
tive as the standard dose of zinc (20 mg/day) in chil-
dren aged 6–59 months, in terms of burden of illness 
(percentage of subjects with diarrhoea lasting >5 days; 
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mean number of loose or watery stools during follow-up) 
and (2) to evaluate the improved effectiveness by reduc-
tion in the risk of vomiting in 30 min after receipt of the 
supplement in low-dose supplemental zinc (5 or 10 mg/
day) in comparison to standard dose of zinc (20 mg/day).
Secondary aims of the study are: (1) to explore whether 
lower doses of zinc have any impact on postacute illness 
morbidity outcomes assessed at 30, 45 and 60 days, (2) 
to explore whether duration of treatment, estimated by 
mother’s reports and collection of used zinc blister packs, 
has any impact on the primary outcomes, (3) to deter-
mine the acceptability of low-dose supplemental zinc 
compared with standard zinc dose based on an accept-
ability scale and (4) to determine whether the different 
doses of zinc are associated with differential plasma zinc 
levels at days 3, 7, 15, 21 and 30 after randomisation.
PArtiCiPAnts/interventions AnD outCoMes
study setting
The study recruitment sites are in South East Asia (SEA) 
and sub-Saharan Africa (SSA). In SEA, the study recruit-
ment sites are located in Sangam Vihar, a resettlement 
colony on outskirts of South Delhi and Harsh Vihar, a 
semi-urban locality in North East District, Delhi, India. 
In SSA, recruitment sites are at health centres in Temeke 
District Hospital, Mbagala Round Table and Mbagala 
Rangi Tatu, Dar es Salaam, Tanzania. Both the sites will 
be recruiting from outpatient health facilities.
eligibility
Study participants will be eligible for enrolment in the 
study if they meet the following inclusion criteria: 1) 
male and female children between 6 and 59 completed 
months of age, 2) acute diarrhoea duration of <72 hours 
at the time of screening (defined as three or more loose 
or watery stools) or dysentery (defined as visible blood 
in the stool), 3) likely to stay within the study area for 
the next 2 months and 4) written informed consent is 
obtained from caretaker.
Children will be excluded if they: (1) have severe acute 
malnutrition (weight for length/height z-score of <−3 
or oedema), (2) have severe dehydration that cannot 
be corrected within 4–6 hours, (3) have signs of severe 
pneumonia (characterised by presence of either chest 
in-drawing and either of the following: convulsions or 
unconscious or vomiting everything,13 sepsis, rapid diag-
nostic test (RDT)-confirmed malaria or other severe 
illness, (4) have previously or currently been enrolled 
in the study, (5) are currently enrolled in another trial, 
(6) are not intending to remain in study area for the 
duration of the study, (7) have a caregiver who declines 
participation in the study, (8) have other child currently 
enrolled in the study in the same household and (9) have 
used zinc supplements during the 3 days preceding study 
enrolment.
sample size
We will enrol 4500 children (1500 per study arm) in the 
trial. Table 1 presents sample size assumptions and calcu-
lations for each of the three primary outcomes. The total 
sample size for the trial was selected to have at least 90% 
power for each of the primary outcomes. The primary 
outcomes (mean number of loose or watery stools 
postrandomisation and percentage of children with 
diarrhoea for >5 days) are both based on the non-inferi-
ority hypotheses, while the primary outcome of vomiting 
postdose assumes a superiority hypothesis. We assumed 
1:1:1 randomisation between the three treatment arms, 
a nominal type I error rate (α) of 0.05% and 5% loss to 
follow-up rate.
interventions
Children are randomised to receive one of the three zinc 
sulfate regimens (each taken once daily for 14 days): (1) 
5 mg; (2) 10 mg or (3) 20 mg. The zinc tablet (all three 
Table 1 Sample size calculations for the primary trial outcomes
Outcome
Value in 
standard dose 
(20 mg/day) 
group
Expected value in 
low-dose groups
Non-inferiority 
margin
Power, significance 
level
Sample size per 
arm
(with ~5% attrition)
Duration of diarrhoea, mean (SD) 3.0 (2.7) days 3.0 (2.7) days
Lower dose equally 
effective
0.3 days 90%, 5% 1460
Percentage of children with 
diarrhoea >5 days
16% 16%
Lower dose equally 
effective
+4% 90%, 5% 1500
Total number of loose or watery 
stools during follow-up, mean 
(SD)
10 (9) stools 10 (9) stools
Lower dose equally 
effective
+2 stools 90%, 5% 1460
Percentage of children with 
vomiting during follow-up
20% 15%
Lower dose safer
Not applicable 
because of 
superiority 
hypothesis for this 
outcome
90%, 5% 1340
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regimens) ingredients include aerosil, maize starch, 
ethylvanillin (a vanilla flavour), aspartame, magnesium 
stearate vegetal and vivapur. The three study tablets have 
identical appearance, taste and smell. The supplement is 
a dispersible tablet that dissolves in water or breast milk 
in about 20 s. The caretakers are instructed to dissolve 
the tablet in 5–10 mL of water or breast milk immediately 
before administration. Children receive zinc supplemen-
tation for 14 days. The first dose of study drug is given at 
the health facility in which the child is enrolled.
All three doses of the regimen are packaged identically; 
10 tablets in 1 blister, 2 blisters in 1 pack (extra doses 
are provided for redosing in case of vomiting). Each 
pack is prelabelled with participant ID. Study regimen 
is manufactured by Laboratoires Pharmaceutiques 
Rodael, France and shipped to WHO for randomisation 
and labelling, before shipment to recruitment sites (as 
described in 'Randomisation, allocation, concealment 
and masking' section).
Adherence assessment
Adherence to the study regimen is optimised by close 
follow-up: either in person (clinic/home visits) or tele-
phone contact on days 3, 5, 7, 10 and 15. Adherence to 
the regimen is measured by counting the numbers of 
unused tablets during each follow-up visit. Study workers/
research assistants physically count the tablets during 
home or clinic visits. We give the mother/caregiver a 
small booklet to record every successful administration 
as well as any failed attempts to administer the interven-
tion. Study worker reviews the diary card on each visit 
and collects filled diary card on day 15 visit.
standard of care
All enrolled children receive standard of care for diar-
rhoea management per WHO/Unicef, Tanzanian and 
Indian Ministry of Health guidelines. This includes 
standardised assessment of hydration status, rehydration 
and maintenance fluids with intravenous or oral rehydra-
tion solutions (ORS) as indicated, recommendation for 
increased fluid intake and continued feeding at home 
and instructions on when to seek follow-up care. Chil-
dren with known HIV receive care and treatment appro-
priate for the child and referral to the care and treatment 
centre nearest to the child’s home.
randomisation, allocation, concealment and masking
Trial arm allocation was performed according to a 
computer-generated randomisation list (generated 
off-site by a non-study statistician) of 4500 individuals, 
stratified by country and child age (>6 to <24 months 
vs >24 to <60 months). A statistician will hold the rando-
misation list codes until completion of primary analyses or 
until requested by the Data and Safety Monitoring Board 
(DSMB). Within each stratum, subjects are randomly 
assigned equally in permuted blocks of variable size to 
receive one of the three doses of zinc. The purpose of 
the stratification is to have equal distribution of younger 
and older children among all three treatment groups. An 
independent pharmacy team prepared the zinc regimen 
in Geneva by labelling blister packs with participant IDs 
based on the randomisation list. Labels were printed 
at WHO, Geneva and enrolled children were assigned 
sequential serial numbers. These prelabelled regimens 
were shipped to the sites in Tanzania and India. The 
packing and physical appearance of the three study 
regimes are identical. In addition, the three doses of the 
regimen are similar in taste, appearance and smell. As a 
result, the research teams, study staff as well as caregivers 
are fully blinded to treatment arm. Zinc formulations are 
serially numbered according to the randomisation codes. 
The code is kept in a password-protected spreadsheet file 
by WHO personnel and is not available to the investiga-
tors until the end of the study. This randomisation list was 
converted into unique sequential serial numbers for each 
enrolled child at each site. This code will only be broken 
if the DSMB requests this information for a participant 
(should they suspect a relationship of a suspected severe 
adverse event [SAE] to the study drug) or for a study arm 
(in their interim analyses).
DAtA ColleCtion, MAnAgeMent AnD AnAlysis
screening and randomisation
Both sites will be recruiting from community clinics. 
Surveillance systems are set up at clinics to identify all 
children presenting with diarrhoea. Trained study staff 
stationed at each health facility are responsible for iden-
tification of children who are potentially eligible. The 
study team is trained in good clinical practice as well as 
confidentiality and research ethics.
Written informed consent is sought from the care-
taker of children meeting the eligibility criteria. A child 
can only be enrolled once into the study. The informed 
consent process includes telling the caretaker that they 
are free to withdraw from the study at any time, and that 
participation is entirely voluntary.
Following consent, each participant will be assigned a 
unique subject identification number. A card detailing 
the subject ID and the health personnel responsible for 
enrolment will be provided to the caregiver of enrolled 
children. The patient locator form/subject master log will 
be the only link between the subject ID and the partici-
pant’s name. This information will be stored together 
with the consent in a locked file cabinet and an online 
database accessible to only the Project Manager and 
required study staff for the purpose of patient tracking.
A baseline assessment, including a detailed physical 
examination (record of vital signs, axillary temperature, 
respiratory rate, pulse rate, hydration and nutritional 
status), will be performed by a research physician at the 
time of screening for enrolment. The child is evaluated for 
any Integrated Management of Childhood Illness general 
danger signs (unable/able to drink or breast feed, convul-
sions, vomiting, unconscious, stiff neck) and evidence of 
dehydration or pneumonia, as well as information on 
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recent medical history (duration of diarrhoea, bloody 
stool/dysentery, recent fever). Vital signs (temperature/
heart rate/respiratory rate) in dehydrated child are 
recorded after the child is rehydrated and stabilised and 
remaining clinical assessment/screening is completed 
thereafter. Anthropometry measurements will be taken 
after rehydration and stabilisation as required, before 
completing the screening for enrolling the participant. 
Weight will be measured using an electronic scale with a 
sensitivity of ±10 g by two independent observers: length 
(for children aged <24 months) or height (for children 
aged 24 months or older), which will be measured using 
a length board within 0.1 cm. Mid-upper arm circumfer-
ence (MUAC) will be measured using non-stretchable 
tape to the nearest 0.1 cm. All anthropometric measures 
will be recorded in duplicate (India) and triplicate 
(Tanzania). Once these measurements and other eligi-
bility criteria are met, the subject will get enrolled.
baseline sociodemographic information and vaccination 
history
Parents of enrolled subjects will be interviewed at study 
clinic or at home for the baseline sociodemographic 
characteristics viz. parent's literacy level and occupation, 
type of house, possession of assets and possible expo-
sures (recent antibiotic use, travel history, water use and 
filtration and sanitation), breast feeding and vaccination 
history and information is recorded in the case record 
forms.
Follow-up visits
Scheduled follow-up visits begin from the third day of the 
enrolment and are generated daily via an automated visit 
generation module of the data management software. All 
children enrolled at the study clinic are to be followed 
up in the clinic or at home by a trained field worker on 
day 3, 5, 7, 10, 15, 30, 45 and 60 (online supplemen-
tary additonal files 1 and 2). In India, study staff will 
visit the household of enrolled children for all follow-up 
visitations. If the child is not available at home, a phone 
call will be made to follow-up the child. In Tanzania, a 
participant will be followed up at home or clinic on days 
3, 7, 15, 30 and 60 and by phone on days 5, 10 and 45. 
Children still having diarrhoea after day 15 are treated 
according to standard management guidelines.8 At each 
visitation during active follow-up period, a study worker 
asks the mother or other caregiver about the following 
and records the responses in a predesigned form/data 
entry module:
1. Ongoing symptoms of diarrhoeal illness, including the 
number and consistency of stools.
2. Vomiting episodes including any episode within 
30 min following zinc administration.
3. Adherence with zinc study regimen ascertained via 
mothers’ recall and/or reported use of zinc tablets 
by the child in the Diarrhoea Diary Card and cross-
checked by determining the number of unused tab-
lets.
4. Any adverse events, including hospital admissions and 
deaths of study participants.
5. Criteria for returning to clinic (eg, lethargy, poor oral 
intake, dehydration).
6. Any other intercurrent illness.
7. Reported use of antibiotics and intravenous/other 
fluids.
At days 30, 45 and 60 postenrolment, the study partici-
pants are assessed either at the study clinic, via telephone 
or with a home visit for presence of any illness, diar-
rhoea, fever, cough or fast or difficult breathing within 
last 24 hours and any time in past 2 weeks. On the day 
60 study completion clinic visit, in addition to morbidity 
assessment, anthropometric measurements will be 
taken for each participant using the same procedure as 
mentioned in the baseline assessment.
Children not available on the visitation day will be 
visited the next day; if they are still not available, they 
are followed-up until found or deemed lost to follow-up. 
Caregivers are asked to contact the study physicians if 
they feel that their children are sick between the visits. 
Children sick on the day of visitation will be referred to 
the study clinic for a detailed morbidity assessment as well 
as treatment by the study physician. During each visit, a 
record of all the medicines and intravenous fluids given, 
information on number and consistency of stools and 
data on adherence is recorded in the predesigned forms. 
Close monitoring will be accomplished through repeated 
follow-ups during the 14-day regimen period. Every 
effort will be made to track and successfully follow-up all 
randomised children.
study withdrawal or discontinuation
The participants have the right to withdraw from the 
study at any time. The subjects will be considered with-
drawn from the trial in case of death or lost to follow-up. 
However, every effort will be made to track and success-
fully follow-up all enrolled children. The information on 
withdrawn or discontinued participants will be recorded 
through a withdrawal slip by field worker and clinic 
supervisor.
blood sampling and laboratory investigations
To allow the measurement of the potential differential 
impact of the varying zinc doses on plasma zinc levels 
during the follow-up period, each study participant will 
provide two blood samples. One-third of the study partic-
ipants will have blood draws at days 1 and 15, one-third at 
days 3 and 21 and the remaining one-third on days 7 and 
30 postenrolment for assessment of plasma zinc levels.
Blood drawing will follow the protocols of the Inter-
national Zinc Nutrition Consultative Group (IZINCG). 
These include use of powder-free gloves, zinc-free 
syringes and butterfly, needles and trace element-
free blood tubes.14 Plasma is separated at 15 min after 
blood collection and aliquots are transferred into 
trace element-free Eppendorf plastic tubes for tempo-
rary storage at −20°C and then shipped to central lab 
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for final storage at −80°C in India. In Tanzania, plasma 
samples are stored in site refrigerators at 2°C–8°C and 
then shipped to central laboratory storage at −80°C by 
the end of the day. Plasma zinc concentrations will be 
measured by atomic absorption spectroscopy (AAS-400 
PerkinElmer, USA).
Quality assurance
The persons with at least a secondary school degree will 
be recruited for data collection team. The following 
quality assurance checks will be done regularly to ensure 
highest level of data integrity and quality:
 ► An extensive 1–3 weeks training session for data 
collectors to ensure the interdata collector reliability 
is above 95%.
 ► Pilot field data testing is monitored closely by the 
research scientist(s) responsible for quality assurance.
 ► Real-time electronic data capture will ensure data 
validation such as range, logical checks and data 
integrity.
 ► Interim aggregate data analysis will be carried out 
periodically for data pattern, heaping, missing values, 
etc. Based on the feedback, effective measures will be 
taken to eliminate/minimise the errors.
For overall visit supervision, quality control (QC) 
supervisors will perform quality checks by visiting at least 
10% of the households, re-interviewing 5% respond-
ents and cross-checking these data with concerned field 
worker. QC supervisors are primarily responsible for 
overall field-related project activities (data quality and 
integration at all levels, resolving community issues), 
and training. Computer randomised list of enrolled 
children will be used by QC team for random house-
hold visits.
The QC team works in close coordination with the inves-
tigative team and provides regular feedback on quality 
issues. Quarterly meetings between QC team and senior 
investigative team are scheduled to discuss overall quality 
issues and related corrective measures to be undertaken.
Data management
Data are collected in real-time using either tablets or 
laptop computers. Each site uses an in-house designed 
data management software with user friendly graphical 
user interface for data collection. Generic case report 
forms and data dictionary are used to maintain data 
consistency across sites. In-built range, logical and skip-
ping pattern will ensure data quality and integrity.
The database is password protected with restricted 
access. Each user is assigned a unique user identifier to 
access the software and an audit trial is maintained for 
database operations. The centralised server located at 
each site synchronises the data on daily basis. Data are 
shared monthly with WHO data quality monitoring team 
who is responsible for data quality checks and provide 
feedback to sites. They generate query forms which are 
returned to the study sites for verification.
Data security and storage
A backup of the data is kept in the server at WHO 
protected by a specific password and accessible to only 
authorised users. An additional backup of the data is kept 
in a password-protected external hard drive at a site away 
from WHO at the recruiting site central offices.
record retention and archival
All the study documents including participant’s source 
data and documents will be archived by the study sites 
after the completion of the study, till the time WHO 
informs in writing to the study sites that they no longer 
need to maintain the study documents.
outcome measures
The primary efficacy outcomes are 1) the percentage of 
enrolled children who have duration of diarrhoea of >5 
days, 2) the mean number of loose or watery stools after 
enrolment and 3) the percentage of children vomiting 
within 30 min of administration of the zinc tablet.
Secondary outcomes of the trial include: i) propor-
tion of children experiencing SAEs (life-threatening 
or hospitalisation); ii) proportion with intermediate 
duration of diarrhoea (diarrhoea continuing beyond 
3 days); iii) proportion of guardians with positive attitude 
towards treatment; iv) treatment adherence; v) mean 
serum plasma zinc concentration at days 1, 3, 7, 15, 21 
and 30; vi) illness symptoms between day 15 and 60 after 
the treatment 2-week period prevalence and number of 
days with diarrhoea, fever or respiratory symptoms; vii) 
60-day change in height/length, weight, MUAC, height/
length-for-age z-score, weight-for-length/height z-score, 
weight-for-age z-score, MUAC z-score, stunting, wasting, 
underweight; viii) adherence to regimen; ix) study drop-
outs; x) maternal report of ease in supplement admin-
istration; xi) maternal report of child acceptability; xii) 
maternal recommendation of use for other children; xiii) 
maternal report of change in child skin condition, child 
appetite, activity levels, mood and diarrhoea severity.
statistical analysis
All primary analyses of non-inferiority tests will be 
conducted on the principle of intention-to-treat (ITT). 
All non-inferiority margins will be defined a priori. We 
will also conduct sensitivity analyses using a per-pro-
tocol (PP) approach.15 The analysis population for the 
ITT approach will include all randomised patients with 
assessable data, regardless of whether the participant is 
known to have received a full 14-day dose of zinc or not. 
The analysis population for the PP approach will include 
study participants who are documented to have taken 
zinc supplementation for the first 5 days after randomi-
sation regardless if they vomited the dose. The PP defi-
nition was selected due to the primary outcome being 
diarrhoea duration >5 days. Descriptive statistics will be 
used to summarise background demographic and base-
line clinical characteristics by trial arm.
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Analysis of primary outcomes
Primary outcome 1
Number (%) of subjects with diarrhoea episodes >5 days. 
The last day of diarrhoea will be defined as the day in which 
there is passage of the last liquid or semi-liquid stool prior 
to two diarrhoea-free days (days when less than three loose 
stools/day). The duration of diarrhoea will be defined as the 
number of days between randomisation (not the reported 
day of onset of diarrhoea symptoms before randomisation) 
and the last day with diarrhoea. Children who are lost to 
follow-up, die or withdraw before 5 days will be excluded 
from this analysis. For the primary analysis, we have set the 
threshold for non-inferiority of lower doses of zinc (10 or 
5 mg/day) as compared with the standard 20 mg/day at 
<4% in absolute risk (risk difference) compared with the 
standard dose in the proportion of subjects with prolonged 
diarrhoea. The proportions of participants with a prolonged 
diarrhoea episode (defined as >5 days) will be calculated 
in all treatment arms, and the risk differences (and their 
95% CIs) between the lower doses (5 and 10 mg/day) and 
the standard dose (20 mg) will be estimated. A Cochran-
Mantel-Haenszel approach will be used to take stratifying 
randomisation factors, for example, country and age 
groups, into account. If the upper limit of the 95% CI for the 
risk difference is <4%, we will conclude non-inferiority for 
one or both lower dose arms. We will also examine the RR 
of prolonged diarrhoea episodes in both lower dose arms 
compared with the standard dose arm using RR regression 
which accounts for factors included in the stratified rando-
misation. In secondary analyses, Cox proportional hazard 
models will be used to estimate HRs and their 95% CIs for 
recovery from diarrhoea in each of the lower dose arms 
compared with the standard dose arm. The time to recovery 
is defined as the duration of diarrhoea as noted above.
Primary outcome 2
Total number of loose or watery stools after enrolment. An 
analysis of covariance (ANCOVA) approach will be used 
to estimate the mean differences and their 95% CI in the 
total number of loose or watery stools after enrolment for 
each lower dose arm compared with the standard dose arm, 
while accounting for the stratified randomisation design. 
The non-inferiority margin was set at two stools, therefore if 
the upper limit of the 95% CI is less than two stools, we will 
reject the null hypothesis that the lower dose zinc is inferior 
to the standard dose in terms of reducing the total number 
of loose or watery stools.
Primary outcome 3
Vomiting within 30 min after administration of the trial 
regimen. We hypothesise that the lower dose of zinc will 
be associated with a reduced risk of vomiting and there-
fore a superiority test will be used. Vomiting within 30 min 
of each daily zinc dose is repeatedly measured during the 
14-day administration period. Generalised estimating 
equations (GEE) with the log link, binomial variance and 
exchangeable correlation matrix will be used to assess 
the RR of vomiting among the three treatment arms. The 
exchangeable working covariance matrix and robust esti-
mators of the variances will be used to construct CIs. The 
robust estimators are consistent estimators of the vari-
ances even if the working correlation matrix is misspec-
ified. Stratified randomisation factors will be considered 
in the model. A secondary analysis concerning severe 
vomiting (defined as vomiting requiring hospitalisation 
or vomiting requiring intravenous fluids) will also be 
performed in similar fashions. We will also examine the 
proportion of children ever vomiting between the treat-
ment arms and examine whether the RR of vomiting 
differs by follow-up day.
Analysis of change in plasma zinc and other secondary 
outcomes
Due to the sampling design of participants having paired 
blood sampled on three schedules (days 1 and 15; days 3 and 
21; days 7 and 30), we will assess the effect of the randomised 
zinc regimen at both the population level and individual 
level. For the analysis of population-level zinc, we will use 
a mixed model approach to compare patterns of plasma 
zinc concentrations over time between the randomised 
treatment arms. The main exposure variables in the model 
will include treatment arm, study day and an interaction 
term between treatment arm and study day. In case there 
is not a linear relationship between study day and plasma 
zinc concentrations, restricted cubic splines will be used to 
examine the non-linear relationship between these two vari-
ables. The interaction term between zinc dose and study day 
in the model measures whether the trajectory of plasma zinc 
differs by zinc supplementation over the full period. If the 
overall test for this interaction term is statistically significant, 
group means at each assessment day will then be compared 
using least-square means with the Tukey-Kramer adjustment. 
To be consistent with our stratified randomisation study 
design, stratification factors will be included in the model.
For all other secondary outcomes (see  clinicaltrial. 
gov NCT03078842), we will use approaches similar to 
the primary analyses, including an ANCOVA approach 
for non-repeated continuous outcomes, RR regression 
for non-repeated binomial outcomes and GEE or mixed 
effect models for repeated longitudinal outcomes.
sensitivity analyses and modification of treatment effect
Although randomisation is designed such that, on 
average, treatment groups will be balanced with respect 
to all baseline prognostic factors, this may not be true in 
all cases. As a result, we will re-assess treatment effects as 
observed in the original analysis after adjusting for factors 
that are potentially imbalanced across randomised arms. 
If imbalance occurs, we will compare and present the 
results for both unadjusted and adjusted analyses.
In addition, the study was not designed to detect effect 
modification of the treatment effect among subgroups of 
children. As a result, we acknowledge that we are likely 
underpowered to detect differences in the magnitude 
of a treatment effect among subgroups unless there 
is strong effect modification. The potential baseline 
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effect modifiers we plan to explore include: study site 
(India/Tanzania), child age (<12 vs >12 months), child 
sex (male vs female), prior receipt of rotavirus vaccine 
(yes vs no), maternal HIV status (yes vs no), dysentery at 
enrolment (yes vs no), baseline dehydration status (yes 
vs no), baseline axillary temperature (<38°C vs >38°C), 
baseline respiratory rate, recent antibiotic use (yes vs 
no), intercurrent illness (cough, difficulty breathing or 
earache), current breastfeeding status (yes vs no) and 
prior breastfeeding status (yes vs no). Additional vari-
ables that we will test for effect modification will include 
child anthropometric measures (length/height for age, 
weight for age and weight for length/height z-scores and 
MUAC), family socioeconomic status (<median wealth 
index, >median wealth index), maternal education, 
household water quality (improved vs unimproved), 
household sanitation quality (improved vs unimproved), 
baseline plasma zinc levels (<median, >median) and trial 
regimen adherence (<median, >median). Factor analysis 
will be used to derive wealth index from family possession 
variables. WHO/Unicef Joint Monitoring Programme 
definitions will be used to clarify improved versus unim-
proved for the household water quality and sanitation.16
Monitoring
Data and Safety Monitoring Board
A Data Safety and Monitoring Board (DSMB) has been 
established to monitor SAEs and to review the statistical 
analysis plan and associated stopping rules for benefit, 
futility or harm determined using O’Brien-Fleming 
stopping boundaries. The DSMB includes five members 
with expertise in clinical trials, statistics, child mortality 
assessment, paediatric care in resource-limited settings or 
practical experience from each study country. The DSMB 
meets electronically or in person at least every 6 months. 
SAEs related to study participation are monitored in real-
time, are summarised and reported to study investigators, 
WHO and relevant institutional review boards (IRBs) 
within 24 hours of notification in India and 72 hours of 
notification in Tanzania. Both sites are required to report 
to WHO within 72 hours of notification. Frequencies 
and descriptions of SAEs are pooled each month by the 
data management team at WHO and circulated to inves-
tigators, DSMB and IRBs. When more than half of the 
person-time is accrued in the study, the DSMB will review 
an interim data analysis by arm to determine whether 
stopping boundaries have been crossed.
Auditing
The sites are responsible for internal quality checks. 
WHO coordinators conduct at least one or two site moni-
toring visits per year to each site.
DisCussion
Zinc supplementation in children during episodes of 
diarrhoea results in several advantages as described 
earlier.1 7 12 Dose recommendations from WHO/Unicef 
were primarily based on previous clinical studies of zinc 
treatment of diarrhoea that used these amounts of zinc. 
Moreover, because zinc is absorbed less efficiently during 
diarrhoea,17 it has been assumed that the therapeutic 
dose for treatment of diarrhoea should be substantially 
greater than the RDA for zinc (3–5 mg/day for children 
aged <5 years), depending on bioavailability from the 
usual diet.9 Therefore, ZTDT was designed to examine 
the optimal therapeutic dose of zinc supplementation for 
children aged under 5 with acute diarrhoea in a south 
Asian country and a sub-Saharan African country.
A recent search of  clinicaltrials. gov found no other 
clinical trials that are determining an optimal zinc ther-
apeutic dose for children with acute diarrhoea. An addi-
tional search on PubMed, Google Scholar and other 
search engines was carried out where it was noted that 
one study was found to determine the optimal dose of 
zinc supplementation in diarrhoea.18 The double-blind 
randomised trial was carried out using 10 or 20 mg zinc 
sulfate versus placebo. No difference in duration nor 
frequency of diarrhoea was noted. However, this study 
was carried out in Switzerland, where the epidemiology 
of acute childhood diarrhoea is different than in India 
or Tanzania. As a result, ZTDT will likely be the first 
randomised trial in low-resource settings to determine 
the optimal dose of therapeutic zinc in children with 
acute diarrhoea.
Overall, the ZTDT study will measure important 
clinical outcomes (outcome of diarrhoea on growth, 
frequency of vomiting) in a large number of children 
under 5 years being treated for acute diarrhoea in India 
and Tanzania. It will also provide evidence for the effect 
of zinc on plasma zinc concentrations over several days 
after supplementation, the effect of zinc on postillness 
outcomes as well as the acceptability of zinc supplementa-
tion. The trial results will be communicated in academic 
journals and at the national and local levels in Tanzania 
and India through policy briefs and dissemination meet-
ings. The results of ZTDT will likely be generalisable to 
children under 5 years with acute diarrhoea in similar 
resource-limited settings and as such will have global rele-
vance. The findings will be an important consideration in 
any further revision of the WHO technical guidelines on 
diarrhoea case management.
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